Find an expert
Our panel of editors are available for interview
Dr Andrea Cipriani
Editor-in-Chief of Evidence-Based Mental Health
Andrea Cipriani, MD, PhD, is Professor of Psychiatry and NIHR Research Professor at the University of Oxford. He is an honorary consultant psychiatrist at the Associate Director for Oxford Health NHS Foundation Trust in Oxford. His main research interests are evidence-based mental health and precision psychiatry. His research focuses on the evaluation of pharmacological, psychological and psychosocial interventions.
Professor Juan Víctor Ariel Franco
Editor-in-Chief of BMJ Evidence-Based Medicine
Professor Juan Franco is a family doctor at the Hospital Italiano de Buenos Aires, Argentina, and Vice-chair of the Research Department at the Instituto Universitario Hispital Italiano (IUHI), where he is also Director of the Cochrane Associate Centre. He is a professor at IUHI and Universidad Nacional de La Matanza, and editor for the Cochrane Urology Group and a member of Cochrane’s Governing Board.
Professor Anna Maria Geretti
Editor-in-Chief of Sexually Transmitted Infections
Anna Maria Geretti, MD, PhD, FRCPath, is Professor of Virology & Infectious Diseases at the Institute of Infection & Global Health of the University of Liverpool, and Honorary Consultant at the Royal Liverpool University Hospital. She trained in Italy, the Netherlands and the UK and has a special interest in HIV, hepatitis B and hepatitis C infection. She has published over 100 peer-reviewed articles, editorials, reviews and book chapters, runs capacity building programmes for resource-limited countries and enthusiastically shares her expertise to train doctors and scientists.
Professor Ganesan Karthikeyan
Editor-in-Chief Open Heart
Professor Karthikeyan is a clinical, interventional cardiologist and a Senior International Fellow of the Population Health Research Institute at McMaster University in Canada, as well as Professor of Cardiology at AIIMS. His research is mainly focused on cardiovascular diseases affecting low and middle income countries, including valvular heart disease, particularly rheumatic heart disease (RHD), mechanical valve thrombosis, anticoagulation, and indigenous drug-eluting stents.
